

Clinical trials of Del-1

TrialResults-center www.trialresultscenter.org

1 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
Del-1 vs placebo			
DELTA (Grossman) , 2007 n=188/188 follow-up: 90 days	plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 versus placebo (poloxamer 188)	patients with bilateral intermittent claudication and peak walking time (PWT) between 1 and 10 minutes on 2 qualifying treadmill tests	double blind

More details and results :

- cell-based therapies for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q335>

References

DELTA (Grossman), 2007:

Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007;153:874-80 [17452167] [10.1016/j.ahj.2007.01.038](https://doi.org/10.1016/j.ahj.2007.01.038)